FIELD: biotechnology.
SUBSTANCE: invention relates to isolated neutralizing antibodies specific to extracellular domains of LSR protein and can be used in medicine. Antibodies and a pharmaceutical composition with a neutralizing activity are obtained via immunization of a mammal with LSR protein with the SEQ ID NO: 11, 13, 15-17 or 18 and subsequent isolation.
EFFECT: invention makes it possible to make pharmaceuticals for immunotherapy which are effective for the treatment of diseases associated with a decreased activation of T-cells mediated by LSR protein.
27 cl, 38 dwg, 20 tbl, 50 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTAGONISTS OF ALK1 RECEPTOR AND LIGANDS AND THEIR APPLICATION | 2007 |
|
RU2559532C2 |
| FUSED PROTEINS CONTAINING PDGF AND VEGF BINDING PARTS, AND METHODS FOR USE THEREOF | 2014 |
|
RU2692652C2 |
| ALK1 ANTAGONISTS AND THEIR APPLICATION IN THE TREATMENT OF KIDNEY-CELLULAR CARCINOMA | 2013 |
|
RU2633638C2 |
| ANTI-SEZ6 ANTIBODIES AND METHODS FOR USING THEM | 2013 |
|
RU2691698C2 |
| MOLECULES WHICH BIND LIGANDS AND USE THEREOF | 2014 |
|
RU2699007C2 |
| HETERODIMERIC IL-15 PROTEIN AND USE THEREOF | 2014 |
|
RU2689717C2 |
| PD1-4-1BBL FUSION PROTEIN AND METHODS OF ITS USE | 2018 |
|
RU2769513C2 |
| FUSED PROTEIN SIRPΑ-4-1BBL AND METHODS OF USING SAME | 2018 |
|
RU2769769C2 |
| TARGETED/IMMUNOMODULATING FUSION PROTEINS AND METHODS FOR THEIR OBTAINING | 2013 |
|
RU2636342C2 |
| HUMANISED ANTI-LIGHT ANTIBODIES AND USING THEM | 2010 |
|
RU2542394C2 |
